Industry Groups Push CMS To Pay For Algorithms In Multi-Analyte Tests
This article was originally published in The Gray Sheet
Executive Summary
The agency’s proposal not to separately pay for the algorithmic analysis that forms the basis of many multi-analyte molecular diagnostic tests misconstrues the nature of the tests, industry groups argue. They call for a final determination by CMS that more truly reflects the value of these assays.